Mid-regional pro-adrenomedullin (MR pro-ADM) is another novel and complex biomarker which has recently gained interest in detecting whether or not it can help the clinician in evaluating not only different forms of infection, but also organ failures and complications in different comorbidities (acute dyspnea, ARDS). This evidence concerns the gene ADM and infection.